PharmAbcine is featured on Pharma Tech Outlook, a monthly magazine that highlights breakthroughs in drug delivery system, pharmaceutical infrastructure, and tools.

The recently released Drug Discovery APAC Edition includes an exclusive article on PMC-403 from PharmAbcine, a first-in-class antibody that binds to the human Tie2 receptor.

The article introduces PMC-403’s unique mode of action and potential indications in both non-ocular and ocular pathological vessel related diseases.

Click the link below for more details.

https://drug-discovery-and-development-apac.pharmatechoutlook.com/vendor/pharmabcine-meeting-unmet-medical-needs-cid-1060-mid-105.html